Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 1/2015

01-01-2015 | Gynecologic Endocrinology and Reproductive Medicine

The risk of ectopic pregnancy following GnRH agonist triggering compared with hCG triggering in GnRH antagonist ivf cycles

Authors: Sadik Sahin, Alev Ozay, Elif Ergin, Lale Turkgeldi, Esra Kürüm, Hakan Ozornek

Published in: Archives of Gynecology and Obstetrics | Issue 1/2015

Login to get access

Abstract

Purpose

The aim of this study was to compare the incidence of ectopic pregnancy in GnRH agonist triggered IVF cycles with intensive luteal support versus hCG triggered IVF cycles.

Methods

This study was conducted as a retrospective cohort analysis of women who underwent IVF treatment employing GnRH agonist or recombinant hCG (rhCG) triggers during 2-year period. The medical charts of women who achieved pregnancies were reviewed and their demographic characteristics, infertility reasons and IVF data were recorded. A multiple logistic regression analysis was performed to estimate the association between the triggering medication used to stimulate final oocyte maturation (GnRHa or rhCG) and EP, with adjustment for important confounders: the day of embryo transfer (ETD), the etiology of infertility and estrogen level at the time of triggering.

Results

The number of metaphase II oocytes, fertilized oocytes and good quality embryos were significantly higher in the GnRH agonist triggered group compared with the hCG triggered group (p < 0.001 for all). The clinical pregnancy and implantation rates in the hCG triggered cycles were 38.6 and 31.1 %, respectively and 24.7 and 22 %, respectively in the triptorelin triggered cycles. The ectopic pregnancy rates were 5.3 % in the triptorelin triggered group and 1.4 % in the hCG triggered group. The trigger medication and the day of embryo transfer were found to have a significant effect on the probability of developing ectopic pregnancy (p = 0.028, p = 0.046 respectively). However, the estrogen level was not found to have a significant effect on the probability of developing ectopic pregnancy (p = 0.447).

Conclusions

The reasons for higher ectopic pregnancy rates in GnRH agonist triggered cycles relative to hCG triggered cycles may be the decreased receptivity of the endometrium due to insufficient luteal support and higher implantation potential of embryos in correlation with a higher number of good quality embryos obtained in these cycles.
Literature
1.
Clayton HB, Schieve LA, Peterson HB, Jamieson DJ, Reynolds MA, Wright VC (2006) Ectopic pregnancy risk with assisted reproductive technology procedures. Obstet Gynecol 107(3):595–604PubMedCrossRef
2.
Chang HJ, Suh CS (2010) Ectopic pregnancy after assisted reproductive technology: what are the risk factors? Curr Opin Obstet Gynecol 22(3):202–207PubMedCrossRef
3.
Itskovitz-Eldor J, Kol S, Mannaerts B (2000) Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod 15(9):1965–1968PubMedCrossRef
4.
Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C (2008) The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 89(1):84–91PubMedCrossRef
5.
Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grøndahl ML, Westergaard L, Andersen CY (2005) GnRH agonist (Buserelin) or HCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomised study. Hum Reprod 20(5):1213–1220PubMedCrossRef
6.
Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, Griesinger G (2005) A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 20(10):2887–2892PubMedCrossRef
7.
Humaidan P, Papanikolaou EG, Tarlatzis BC (2009) GnRH agonist to triggered final oocyte maturation: a time to reconsider. Hum Reprod 24(10):2389–2394PubMedCrossRef
8.
Cutting R, Morroll D, Roberts SA, Pickering S, Rutherford A (2008) Elective single embryo transfer: guidelines for practice British Fertility Society and Association of Clinical Embryologists. Hum Fertil (Camb) 11(3):131–146CrossRef
9.
Imoedemhe DA, Sigue AB, Pacpaco EL, Olazo AB (1991) Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in vitro fertilization. Fertil Steril 55(2):328–332PubMed
10.
Oktay K, Türkçüoğlu I, Rodriguez-Wallberg Kenny A (2010) GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod BioMed Online 20(6):783–788PubMedCentralPubMedCrossRef
11.
Kol S, Humaidan P (2010) LH (as HCG) and FSH surges for final oocyte maturation: sometimes it takes two to tango? Reprod Biomed Online 21(5):590–592PubMedCrossRef
12.
Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, Brooks B, Mimoni T, Eldar-Geva T (2006) Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 21(5):1260–1265PubMedCrossRef
13.
Orvieto R, Rabinson J, Meltzer S, Zohav E, Anteby E, Homburg R (2006) Substituting HCG with GnRH agonist to trigger final follicular maturation—a retrospective comparison of three different ovarian stimulation protocols. Reprod Biomed Online 13(2):198–201PubMedCrossRef
14.
Orvieto R (2012) Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help? Reprod Biomed Online 24(6):680–681PubMedCrossRef
15.
Imbar T, Kol S, Lossos F, Bdolah Y, Hurwitz A, Haimov- Kochman R (2012) Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support. Hum Reprod 27(3):753–759PubMedCrossRef
16.
Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM (1991) Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 56(2):213–220PubMed
17.
Iliodromiti S, Blockeel C, Tremellen KP, Fleming R, Tournaye H, Humaidan P, Nelson SM (2013) Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Hum Reprod 28(9):2529–2536PubMedCrossRef
18.
19.
Kummer N, Benadiva C, Feinn R, Mann J, Nulsen J, Engmann L (2011) Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist. Fertil Steril 96:63–68PubMedCrossRef
20.
Humaidan P, Bredkjaer HE, Westergaard LG, Andersen CY (2010) 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 93(3):847–854PubMedCrossRef
21.
Bermejo A, Cerrillo M, Ruiz-Alonso M, Blesa D, Simón C, Pellicer A, Garcia-Velasco JA (2014) Impact of final oocyte maturation using gonadotropin-releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression. Fertil Steril 101(1):138–146.e3PubMedCrossRef
22.
Humaidan P, Van Vaerenbergh I, Bourgain C, Alsbjerg B, Blockeel C, Schuit F (2012) Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist cotreated IVF cycles. Hum Reprod 27(11):3259–3272PubMedCrossRef
23.
Fernandez H, Coste J, Job-Spira N (1991) Controlled ovarian hyperstimulation as a risk factor for ectopic pregnancy. Obstet Gynecol 78(4):656–659PubMed
24.
Pyrgiotis E, Sultan KM, Neal GS, Liu HC, Grifo JA, Rosenwaks Z (1994) Ectopic pregnancies after in vitro fertilization and embryo transfer. J Assist Reprod Genet 11(2):79–84PubMedCrossRef
25.
Marcus SF, Brinsden PR (1995) Analysis of the incidence and risk factors associated with ectopic pregnancy following in vitro fertilization and embryo transfer. Hum Reprod 10(1):199–203PubMedCrossRef
26.
Wang J, Wei Y, Diao F, Cui Y, Mao Y, Wang W, Liu J (2013) The association between polycystic ovary syndrome and ectopic pregnancy after in vitro fertilization and embryo transfer. Am J Obstet Gynecol 209(2):139.e1–139.e9CrossRef
27.
Wu Z, Li R, Ma Y, Deng B, Zhang X, Meng Y, Chen X, Liu P, Qiao J (2012) Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles. Reprod Biomed Online 24(5):511–520PubMedCrossRef
28.
Zhu L, Li Y, Xu A (2012) Influence of controlled ovarian hyperstimulation on uterine peristalsis in infertile women. Hum Reprod 27(9):2684–2689PubMedCrossRef
Metadata
Title
The risk of ectopic pregnancy following GnRH agonist triggering compared with hCG triggering in GnRH antagonist ivf cycles
Authors
Sadik Sahin
Alev Ozay
Elif Ergin
Lale Turkgeldi
Esra Kürüm
Hakan Ozornek
Publication date
01-01-2015
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 1/2015
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-014-3399-x

Other articles of this Issue 1/2015

Archives of Gynecology and Obstetrics 1/2015 Go to the issue

General Gynecology

Detection of the pan neuronal marker PGP9.5 by immuno-histochemistry and quantitative PCR in eutopic endometrium from women with and without endometriosis

Acknowledgement to Referees

Reviewers 2014

Gynecologic Endocrinology and Reproductive Medicine

Routine office hysteroscopy prior to ICSI vs. ICSI alone in patients with normal transvaginal ultrasound: a randomized controlled trial

General Gynecology

Minimally invasive cystocele repair technique using a polypropylene mesh introduced with the transobturator route

Gynecologic Endocrinology and Reproductive Medicine

Endometrial preparation protocol of the frozen-thawed embryo transfer in patients with polycystic ovary syndrome

General Gynecology

An atresia cervix removal, lower uterine segment substitute for cervix and uterovaginal anastomosis: a case report and literature review